HuGE Literature Finder
Records
1
-
30
| Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma. Virchows Archiv : an international journal of pathology 2022 Jun . Yamashita Atsushi, Suehara Yoshiyuki, Hayashi Takuo, Takagi Tatsuya, Kubota Daisuke, Sasa Keita, Hasegawa Nobuhiko, Ishijima Muneaki, Yao Takashi, Saito Tsuyos |
| Association of Pathway Mutations With Survival in Taiwanese Breast Cancers. Frontiers in oncology 2022 12 819555. Yang Po-Sheng, Chao Ying-Ting, Lung Chun-Fan, Liu Chien-Liang, Chang Yuan-Ching, Li Ker-Chau, Hsu Yi-Chiu |
| Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing. Cancer cell international 2021 Jan 21 (1): 23. Shao Yanxiang, Hu Xu, Yang Zhen, Lia Thongher, Yang Weixiao, Wu Kan, Ren Shangqing, Xiong Sanchao, Dou Weichao, Feng Shuyang, Wang Yaohui, Liu Yang, Wu Kang, Li Xia |
| Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. Frontiers in oncology 2020 10 755. Hayashi Yujiro, Fujita Kazutoshi, Matsuzaki Kyosuke, Eich Marie-Lisa, Tomiyama Eisuke, Matsushita Makoto, Koh Yoko, Nakano Kosuke, Wang Cong, Ishizuya Yu, Kato Taigo, Hatano Koji, Kawashima Atsunari, Ujike Takeshi, Uemura Motohide, Imamura Ryoichi, Netto George J, Nonomura Nor |
| SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change. Investigative and clinical urology 2019 May 60 (3): 148-155. Kim Sung Han, Park Weon Seo, Chung Jins |
| Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. BJU international 2019 May . Ward D G, Gordon N S, Boucher R H, Pirrie S J, Baxter L, Ott S, Silcock L, Whalley C M, Stockton J D, Beggs A D, Griffiths M, Abbotts B, Ijakipour H, Latheef F N, Robinson R, White A J, James N D, Zeegers M P, Cheng K K, Bryan R |
| Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential. Histopathology 2017 Nov . Wang Chung-Chieh, Huang Chao-Yuan, Jhuang Yu-Lin, Chen Chih-Chi, Jeng Yung-Mi |
| FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Cancer science 2016 Sep . Hibi Masaaki, Kaneda Hiroyasu, Tanizaki Junko, Sakai Kazuko, Togashi Yosuke, Terashima Masato, De Velasco Marco Antonio, Fujita Yoshihiko, Banno Eri, Nakamura Yu, Takeda Masayuki, Ito Akihiko, Mitsudomi Tetsuya, Nakagawa Kazuhiko, Okamoto Isamu, Nishio Kazu |
| Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma. Human pathology 2016 May . Li Chengfang, Shen Yaoyuan, Ren Yan, Liu Wei, Li Man, Liang Weihua, Liu Chunxia, Li Fe |
| The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients. Oncotarget 2016 Mar . Yuan Xiaotian, Liu Cheng, Wang Kun, Liu Li, Liu Tiantian, Ge Nan, Kong Feng, Yang Liu, Björkholm Magnus, Fan Yidong, Zhao Shengtian, Xu Daw |
| Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. Oncotarget 2016 Feb . Iacono Marco Lo, Buttigliero Consuelo, Monica Valentina, Bollito Enrico, Garrou Diletta, Cappia Susanna, Rapa Ida, Vignani Francesca, Bertaglia Valentina, Fiori Cristian, Papotti Mauro, Volante Marco, Scagliotti Giorgio V, Porpiglia Francesco, Tucci Marcel |
| Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. The Journal of urology 2016 Jan . Bagrodia Aditya, Cha Eugene K, Sfakianos John P, Zabor Emily C, Bochner Bernard H, Al-Ahmadie Hikmat A, Solit David B, Coleman Jonathan |
| Genetic diversity of urinary bladder cancer and the risk of recurrence based on mutation analysis. Neoplasma 2016 63 (6): 952-960. Traczyk-Borszynska M, Borkowska E, Jablonowski Z, Jedrzejczyk A, Pietrusinski M, Kaluzewski B, Sosnowski M, Borowiec |
| Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget 2015 Oct . Wang Rui, Zhang Yang, Pan Yunjian, Li Yuan, Hu Haichuan, Cai Deng, Li Hang, Ye Ting, Luo Xiaoyang, Zhang Yiliang, Li Bin, Shen Lei, Sun Yihua, Chen Haiqu |
| Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. International journal of cancer. Journal international du cancer 2015 Oct 137 (7): 1621-9. Hosen Ismail, Rachakonda P Sivaramakrishna, Heidenreich Barbara, de Verdier Petra J, Ryk Charlotta, Steineck Gunnar, Hemminki Kari, Kumar Raj |
| The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study. Urology 2015 Sep . Couffignal Camille, Desgrandchamps François, Mongiat-Artus Pierre, Ravery Vincent, Ouzaid Idir, Roupret Morgan, Phe Véronique, Ciofu Calin, Tubach Florence, Mentre France, Cussenot Olivier, Grandchamp Berna |
| PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Molecular carcinogenesis 2015 Jul 54 (7): 566-76. Dueñas Marta, Martínez-Fernández Mónica, García-Escudero Ramón, Villacampa Felipe, Marqués Miriam, Saiz-Ladera Cristina, Duarte José, Martínez Victor, Gómez M José, Martín M Luisa, Fernández Manoli, Castellano Daniel, Real Francisco X, Rodriguez-Peralto Jose L, De La Rosa Federico, Paramio Jesús |
| Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015 Jun 28 (6): 836-44. Stelloo Ellen, Bosse Tjalling, Nout Remi A, MacKay Helen J, Church David N, Nijman Hans W, Leary Alexandra, Edmondson Richard J, Powell Melanie E, Crosbie Emma J, Kitchener Henry C, Mileshkin Linda, Pollock Pamela M, Smit Vincent T, Creutzberg Carien |
| Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget 2015 Feb 6 (4): 2562-72. Kim Hyo Song, Lee Seung Eun, Bae Yoon Sung, Kim Dae Joon, Lee Chang-Geol, Hur Jin, Chung Hyunsoo, Park Jun Chul, Jung Da Hyun, Shin Sung Kwan, Lee Sang Kil, Lee Yong Chan, Kim Hye Ryun, Moon Yong Wha, Kim Joo Hang, Shim Young Mog, Jewell Susan S, Kim Hyunki, Choi Yoon-La, Cho Byoung Ch |
| Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. European urology 2014 Feb 65 (2): 360-6. Allory Yves, Beukers Willemien, Sagrera Ana, Flández Marta, Marqués Miriam, Márquez Mirari, van der Keur Kirstin A, Dyrskjot Lars, Lurkin Irene, Vermeij Marcel, Carrato Alfredo, Lloreta Josep, Lorente José A, Carrillo-de Santa Pau Enrique, Masius Roy G, Kogevinas Manolis, Steyerberg Ewout W, van Tilborg Angela A G, Abas Cheno, Orntoft Torben F, Zuiverloon Tahlita C M, Malats Núria, Zwarthoff Ellen C, Real Francisco |
| Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. Genetics and molecular research : GMR 2014 13 (1): 1109-20. Liu X, Zhang W, Geng D, He J, Zhao Y, Yu |
| Mutations of fibroblast growth factor receptor 3 gene (FGFR3) in transitional cell carcinoma of urinary bladder in Thai patients [Revision-2a]. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2013 Aug 96 (8): 8. Jantip J, Tanthanuch M, Kanngurn S, Karnchanawanichkul W, Pripatnanont C, Sangkhathat S, Thongsuksai P |
| Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. The Journal of urology 2013 May 189 (5): 1945-51. Zuiverloon Tahlita C M, Beukers Willemien, van der Keur Kirstin A, Nieuweboer Annemieke J M, Reinert Thomas, Dyrskjot Lars, Orntoft Torben F, Zwarthoff Ellen |
| CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. The Journal of pathology 2012 Jul 227 (3): 315-24. Rebouissou Sandra, Hérault Aurélie, Letouzé Eric, Neuzillet Yann, Laplanche Agnès, Ofualuka Karina, Maillé Pascale, Leroy Karen, Riou Audrey, Lepage May-Linda, Vordos Dimitri, de la Taille Alexandre, Denoux Yves, Sibony Mathilde, Guyon Frédéric, Lebret Thierry, Benhamou Simone, Allory Yves, Radvanyi Franço |
| The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22. American journal of cancer research 2011 1 (4): 498-507. Ploussard Guillaume, Soliman Hany, Dubosq Francis, Méria Paul, Vérine Jérôme, Desgrand-Champs François, Dethé Hugues, Mongiat-Artus Pier |
| Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. European urology 2010 Sep 58 (3): 433-41. van Rhijn Bas W G, Zuiverloon Tahlita C M, Vis André N, Radvanyi François, van Leenders Geert J L H, Ooms Bert C M, Kirkels Wim J, Lockwood Gina A, Boevé Egbert R, Jöbsis Adriaan C, Zwarthoff Ellen C, van der Kwast Theo |
| Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jun 16 (11): 3011-8. Zuiverloon Tahlita C M, van der Aa Madelon N M, van der Kwast Theo H, Steyerberg Ewout W, Lingsma Hester F, Bangma Chris H, Zwarthoff Ellen |
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer.
Nature genetics 2010 May 42 (5): 415-9. Kiemeney Lambertus A, Sulem Patrick, Besenbacher Soren, Vermeulen Sita H, Sigurdsson Asgeir, Thorleifsson Gudmar, Gudbjartsson Daniel F, Stacey Simon N, Gudmundsson Julius, Zanon Carlo, Kostic Jelena, Masson Gisli, Bjarnason Hjordis, Palsson Stefan T, Skarphedinsson Oskar B, Gudjonsson Sigurjon A, Witjes J Alfred, Grotenhuis Anne J, Verhaegh Gerald W, Bishop D Timothy, Sak Sei Chung, Choudhury Ananya, Elliott Faye, Barrett Jennifer H, Hurst Carolyn D, de Verdier Petra J, Ryk Charlotta, Rudnai Peter, Gurzau Eugene, Koppova Kvetoslava, Vineis Paolo, Polidoro Silvia, Guarrera Simonetta, Sacerdote Carlotta, Campagna Marcello, Placidi Donatella, Arici Cecilia, Zeegers Maurice P, Kellen Eliane, Gutierrez Berta Saez, Sanz-Velez José I, Sanchez-Zalabardo Manuel, Valdivia Gabriel, Garcia-Prats Maria D, Hengstler Jan G, Blaszkewicz Meinolf, Dietrich Holger, Ophoff Roel A, van den Berg Leonard H, Alexiusdottir Kristin, Kristjansson Kristleifur, Geirsson Gudmundur, Nikulasson Sigfus, Petursdottir Vigdis, Kong Augustine, Thorgeirsson Thorgeir, Mungan N Aydin, Lindblom Annika, van Es Michael A, Porru Stefano, Buntinx Frank, Golka Klaus, Mayordomo José I, Kumar Rajiv, Matullo Giuseppe, Steineck Gunnar, Kiltie Anne E, Aben Katja K H, Jonsson Eirikur, Thorsteinsdottir Unnur, Knowles Margaret A, Rafnar Thorunn, Stefansson Ka |
| Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer science 2010 Jan 101 (1): 250-8. Miyake Makito, Sugano Kokichi, Sugino Hitomi, Imai Kazuho, Matsumoto Eri, Maeda Koshi, Fukuzono Shinich, Ichikawa Hiroki, Kawashima Kiyotaka, Hirabayashi Kaoru, Kodama Tetsuro, Fujimoto Hiroyuki, Kakizoe Tadao, Kanai Yae, Fujimoto Kiyohide, Hirao Yoshihi |
| FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PloS one 2010 5 (11): e13821. Kompier Lucie C, Lurkin Irene, van der Aa Madelon N M, van Rhijn Bas W G, van der Kwast Theo H, Zwarthoff Ellen |
- Page last reviewed:Jul 25, 2022
- Page last updated:Dec 06, 2022
- Content source: